IVCC/CCSVI, articles et liens de ce mercredi.

Publié le par Handi@dy

Barre google de traduction indispensable!

*"

Manif | Sclérose en plaques

Beaucoup d’émotion

19/10/2010 14h41 

Une foule importante, pancartes en main, s’est massée devant le Parlement, mardi après-midi, pour demander au gouvernement d’aller de l’avant avec la méthode Zamboni.
© Simon Clark

À lire aussi

Entre les chaises roulantes, les marchettes et les affiches, l’émotion était palpable, mardi, devant l’Assemblée nationale, alors que plus de 300 personnes de partout au Québec − malades atteints de la sclérose en plaques, amis et familles – ont demandé haut et fort au gouvernement que soit appliquée dans les plus brefs délais la méthode de traitement du Dr Zamboni, contestée au Canada.

Un traitement dont a bénéficié, le 18 mai, en Pologne, Francine Deshaies, l’organisatrice de ce grand mouvement de foule. Selon elle, pas moins de 250 Québécois auraient traversé les frontières à ce jour pour subir l’intervention, que ce soit en Inde, en Bulgarie, en Égypte, au Costa Rica ou aux États-Unis.

Elle a déboursé 12 000 $, de ses poches, pour subir le traitement qui a littéralement « changé sa vie ». Depuis, fini les journées à rester couchée, la chaise roulante, les problèmes de vessie et les migraines.

Francine Deshaies, atteinte depuis 18 ans par la maladie, marche désormais avec une canne. « C’est le jour et la nuit. J’ai une qualité de vie que je n’avais pas avant. J’ai tellement d’amélioration », se réjouit la femme originaire de Saint-Lambert.

Problèmes de circulation

Selon le médecin italien Paulo Zamboni, la sclérose en plaques pourrait être causée par une perturbation de la circulation sanguine qui entraînerait une incapacité du système veineux à drainer le sang du cerveau. Pour pallier le problème, le chirurgien vasculaire pratique l’angioplastie, une technique consistant à introduire un ballon dans les veines afin de les débloquer.

 

Si l’intervention est possible à l’étranger, le suivi médical en terre québécoise semble toutefois difficile. « Quand je suis revenue, personne ne voulait me voir. On me disait de retourner en Pologne. On refusait de me traiter. Il a fallu que je me batte tout l’été », affirme cette mère de famille qui a finalement pu dénicher une hématologue pour s’occuper d’elle.

Ça presse!

Pour plusieurs personnes atteintes de la sclérose en plaques, le temps presse. C’est le cas de Brenda Deblois, atteinte du niveau le plus sévère de la maladie, détectée il y a un an et demi.

« Je suis le 46e cas au monde. Il y a deux ans, je pétais le feu! Aujourd’hui, je suis sur la morphine 24 heures sur 24; la prochaine étape pour moi, c’est le gavage », se désole la femme, confinée à la chaise roulante.

Dans un témoignage poignant, la femme a affirmé que la méthode du Dr Zamboni demeurerait son seul espoir. Elle se trouve sur une liste d’attente pour une intervention, à Albany, aux États-Unis. « On se sent abandonnés. Il faut apporter la technique ici. Ce qu’ils font, c’est ne pas prêter assistance à une personne en danger. C’est criminel », plaide-t-elle.

Différentes études vont à l'encontre de la méthode Zamboni, ce qui semble avoir refroidi le Canada pour aller de l’avant dans cette histoire."

*

MS therapy's value is clear, except to Ottawa

 

'Liberation treatment' shown to reduce symptoms of disease

*

New oral MS drug cladribine rejected by regulators

*"

par MS Society of Canada - Alberta Division ccsvi, mardi 19 octobre 2010, à 23:52

Recently, the MS Society of Canada, Alberta & Northwest Territories Division contacted the Canada Revenue Agency on behalf of those asking if CCSVI medical expenses for treatment obtained outside Canada could be claimed on their Income Tax Return.  The individual we spoke to said that it appeared that such expenses were eligible for a tax credit, and possibly associated travel expenses too.  He did however suggest that all inquiries should first be directed to CRA prior to filing a tax return. "

*MS Patients the Real Sufferers

The MS Society has come in for sharp criticism yet again, after it has asked for donations regarding a new initiative. The society has this time asked for help regarding a commitment made by the society for donating $2.4 million for a research in CCSVI.

The continuous demands by the MS Society have been going on since the past forty years. However, there still has not been any visible progress in the fight against multiple sclerosis, despite the donation of money amounting to billions of dollars. The undergoing research work has still not been able to find a permanent cure for the ailment.

It also needs to be pointed out that the government itself is not ready to help the research work, as it has announced that it won’t allow clinical tests for the CCSVI research. One thing that really hints a reason behind the government’s decision could be the fact that pharmaceutical Companies both in the US and in Canada rake in millions of dollars in revenue through the sale of medicines for MS.

A permanent cure for the disease could result in the revenue coffers for the pharmaceutical companies seeing a drop in profits.

 

The Annette Funicello family donated $10, 000 to Dr Dake's upcoming clinical research

*

Announcement set on MS research

*"

Blood Lipids Linked With Disease Progression Risk in MS: Presented at ECTRIMS

By David S. MacDougall

GOTHENBURG, Sweden -- October 17, 2010 -- Clinical outcomes in patients with multiple sclerosis (MS) are adversely affected by increased blood levels of low-density lipoprotein (LDL), total cholesterol, and triglycerides, researchers said here on October 14 at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Dyslipidaemia independently predicts an increased risk for cardiovascular complications via mechanisms related to activation of inflammatory processes at the vascular endothelial level, said lead study author Bianca Weinstock-Guttman, MD, Jacobs Neurological Institute, Buffalo, New York.

The risk of disease progression in patients with MS has recently been linked to vascular comorbidities, she noted, but the mechanisms underlying this association remain uncertain.

"Cholesterol is an important component of intact myelin," Dr. Weinstock-Guttman said. "Lipids, especially lipoproteins, are involved in the regulation of several neural functions through local independent mechanisms that are linked to systemic lipid metabolism in the CNS [central nervous system]."

Dr. Weinstock-Guttman and colleagues retrospectively examined blood lipid profiles from 521 patients with MS. A baseline Expanded Disability Status Scale (EDSS) assessment was available at the time of blood lipid profile analysis and at >=6 months following the initial evaluation.

Statin usage was documented in 22.2% of the study group.

Increases in EDSS at follow-up (mean, 2.2 years) were significantly associated with higher baseline LDL cholesterol (P =.018), triglyceride (P =.011), and total cholesterol levels (P =.003). EDSS changes were not associated with baseline high-density lipoprotein (HDL) cholesterol levels.

Similarly, increases in MS Severity Scale scores were significantly associated with higher baseline LDL cholesterol (P =.036), triglycerides (P =.018), and total cholesterol levels (P =.022), but not baseline HDL cholesterol levels.

Higher triglyceride levels at baseline were associated with a significantly increased probability (P =.023) for the presence of contrast-enhancing lesions (CEL) on magnetic resonance imaging of the brain at baseline. In contrast, higher HDL cholesterol levels were associated with a significantly lower probability (P =.01) for the presence of CEL.

No association was found between the risk of MS disease progression and body mass index at baseline or statin treatment.

The researchers concluded that lifestyle changes designed to maintain blood lipid profiles within recommended ranges might be useful in patients with MS.

Funding for this study was provided by Biogen Idec, Teva Neuroscience, EMD Serono, Pfizer, Novartis, sanofi-aventis, and Questcor Pharmaceuticals.

[Presentation title: Association of Serum Cholesterol With Clinical Outcomes in Multiple Sclerosis. Abstract P573]

"
*
 
Living with Multiple Sclerosis

Printer Friendly Page

  Small FontMedium FontLarge Font

Education

*

Commenter cet article